Study design Origin of patients TB-IRIS group N Control group (non-IRIS)N Time between HAART onset and IRIS (days) CD4+ T-lymphocyte (at pre-HAART) (cell/mm3) CD4+ T-lymphocyte (at IRIS) (cell/ mm3) References Case report England 1 2 35 150 294 [37] Prospective Sub-Saharan Africa* 7 (pIRIS) 12 23 32 107 [18] Prospective Malaysia† 3 (pIRIS) 8 Patient 1: 21 NI NI [30] Patient 2: 84 Patient 3: 98 Prospective Sub-Saharan Africa* 11 (pIRIS) 13 23 26 86 [21] Cross-sectional South Africa 35 (pIRIS) 19 14 51 181 [20] Prospective 10 (pIRIS) 41 15 195 NI Prospective Sub-Saharan Africa* 11 (pIRIS) 13 26 37 108 [22] Prospective Cambodia§ 15 (pIRIS) 55 10 45 NR [31] 11 (uIRIS) 206 10 Prospective Thailand 22 (pIRIS) 104 14 35 144 [32] Prospective Cambodia§ 15 (pIRIS) 30 10 45 NI [33] Prospective Cambodia§ 15 (pIRIS) 30 10 45 NI [19] Case report Thailand 1 (uIRIS) 4 60 46 155 [34] Case report South Africa 22 (pIRIS) 22 14 NI NI [23] Prospective Malaysia† 3 (pIRIS) 9 49 15 147 [35] Case-control South Africa 18 (uIRIS) 58 (HIV) 55 115 154 [24] 51 (HIV-TB) Prospective South Africa 1 (uIRIS) NI 28 4 41 [25] 5(pIRIS) 42 Prospective South Africa 8 (TB-MDR) 25 (TB-FS) 14 50 NI [26] 3 (TB-RM) 55 Prospective Cambodia§ 15 (pIRIS) 30 10 45 NI [36] Prospective South Africa 16 18 14 93 158 [27] Prospective Gambia 20 (pIRIS) 16 21 60 180 [28] Prospective Uganda 18 (pIRIS) 18 14 19 NI [29] pIRIS: tuberculosis associated with paradoxical IRIS; uIRIS: tuberculosis associated with unmasking IRIS; NI: Not Informed; TB-MDR: Tuberculosis Multi-Drug Resistant; TB-RM: Tuberculosis Mono-Resistant to Rifampicin; TB-FS: Tuberculosis Full Sensitive;*, †, §patients evaluated in the same studies.

Table 1: Characteristics of included studies.